Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06406556
Status:
RECRUITING
Last Update Posted:
2024-05-09
First Post:
2024-05-06
Brief Title:
Safety Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Evaluate the Safety and Efficacy of Pegaspargase-based Concurrent Chemoradiotherapy in the Treatment of Early Stage Extranodal NKT Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENKTL
Brief Summary:
The purpose of this multi-center single arm phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of concurrent chemoradiotherapy by using single-drug pegaspargase for patients with ENKTL in stage IE to IIE
Detailed Description:
The treatment regimen included CCRT involved field radiotherapy 50GY concurrent 2 cycles of pegaspargase treatment followed by 4 cycles of pegaspargase Chemotherapy and RT were performed simultaneously within one week after enrollment The administration regimen was as follows day1 deep intramuscular injection of 2500 unitm2 pegaspargase at three different sites and repeated once every 3 weeks 3D conformal radiotherapy was performed using 4 or 6 MV photons generated by a linear accelerator The radiation dose was 50 Gy 20 Gy time 1 time d for 5 weeks The clinical target volume CTV of limited stage IE patients was defined as bilateral nasal cavity bilateral ethmoid sinus and ipsilateral maxillary sinus The CTV of extensive stage IE patients was extended to the affected tissues The CTV of stage IIE lesions also included the involved cervical lymph node area
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None